Could the speed of blood sugar drop harm the eyes? a study puts it to the test.

NCT ID NCT07723820

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study investigates whether the speed at which blood sugar falls after starting a new diabetes medicine affects small blood vessels in the eye. Adults with type 2 diabetes who are beginning a GLP-1 receptor agonist or an SGLT2 inhibitor will undergo advanced eye scans and blood tests over several months. The goal is to see if a faster drop in blood sugar, rather than the specific drug, is linked to early changes in retinal blood flow. Findings could help guide safer treatment strategies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GLP-1 receptor agonists or SGLT2 inhibitors, prescribed as part of routine care
What this could lead to
If the speed of blood sugar reduction drives early eye changes, doctors may adjust how quickly they intensify treatment to protect vision.
What could go wrong
This is an observational study that does not control which drug is given, so it cannot prove cause and effect. Results may not apply to people with more advanced eye disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY (DR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Faculty of Medicine, Thammasat University

    Pathum Thani, Khlong Luang, 12120, Thailand

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.